Company: VMCWF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001827
Chunk: 523

Company: Valuence Merger Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 523
---
 Directors since our inception. Mr. Hyung has
significant experience sourcing, structuring, and executing complex transactions across the sustainability and technology value chain.
Most recently, Mr. Hyung was at Nomura Greentech, a sustainable technology and infrastructure investment bank, responsible for executing
multiple M&A transactions and origination efforts within the energy transition and clean technology sectors. He executed multiple
de-SPAC transactions and was part of the SPAC coverage team that was responsible for completing approximately a quarter of all sustainability-related
SPAC business combinations and de-SPAC transactions. Prior to Nomura Greentech, Mr. Hyung was at Deutsche Bank, where he focused on origination
and execution of M&A, debt and equity financing across the technology, media, and telecommunications sectors. Mr. Hyung received
his B.A. from University of Toronto and M.B.A. from Cornell University.

Sungsik
(Sung) Lee has been our President since our inception. Mr. Lee brings extensive experience in investment banking, venture capital,
and corporate development, with a proven track record of sourcing and executing M&A, strategic investment, and financing transactions.
Most recently, Mr. Lee led cross-border M&A and strategic investments across the broad sustainability-focused areas at the Global
Development Group of SK, the third-largest conglomerate in Korea with more than 100 affiliates over diverse sectors including energy,
ICT, and life sciences. Prior to SK, Mr. Lee was at SunTrust Robinson Humphrey, where he advised many publicly traded industrial companies
on M&A and capital market transactions. Before joining SunTrust, Mr. Lee was at Progress Partners, a media and technology-focused
investment banking firm, where he executed M&A and financing projects for early-to-mid-stage clients and managed three investment
funds at Progress Ventures, its affiliated venture capital arm. Mr. Lee received his B.A. from Hanyang University and M.B.A. from Cornell
University.

Dr.
Gene Young Cho has been our Chief Operating Officer since our inception. Dr. Gene Young Cho brings leadership and experience
in business operations and life sciences. Currently, he is the Executive Director of CG Pharmaceuticals, Inc., the U.S. subsidiary of
CrystalGenomics. In this role, Dr. Cho is focused on developing growth strategies as well as providing strategic planning and management
of the operations and expansion of CG Pharmaceuticals. Previously, Dr. Cho worked as a life sciences consultant at L.E.K. Consulting,
working with clients in biopharmaceutical